CN116348144A - 用于呼吸道免疫病理学的吸入性il-1阻滞治疗 - Google Patents

用于呼吸道免疫病理学的吸入性il-1阻滞治疗 Download PDF

Info

Publication number
CN116348144A
CN116348144A CN202180059453.XA CN202180059453A CN116348144A CN 116348144 A CN116348144 A CN 116348144A CN 202180059453 A CN202180059453 A CN 202180059453A CN 116348144 A CN116348144 A CN 116348144A
Authority
CN
China
Prior art keywords
rhil
nebulizer
group
ira
anakinra
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180059453.XA
Other languages
English (en)
Chinese (zh)
Inventor
S·A·瑞宁
L·A·巴拉诺夫斯基
K·R·克里泽
M·帕拉西奥斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Autowan Science Co ltd
Original Assignee
Autowan Science Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Autowan Science Co ltd filed Critical Autowan Science Co ltd
Publication of CN116348144A publication Critical patent/CN116348144A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202180059453.XA 2020-05-21 2021-05-20 用于呼吸道免疫病理学的吸入性il-1阻滞治疗 Pending CN116348144A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063028494P 2020-05-21 2020-05-21
US63/028,494 2020-05-21
US202063072895P 2020-08-31 2020-08-31
US63/072,895 2020-08-31
PCT/IB2021/000347 WO2021234457A1 (en) 2020-05-21 2021-05-20 An inhaled il-1 blockade treatment for respiratory tract immunopathology

Publications (1)

Publication Number Publication Date
CN116348144A true CN116348144A (zh) 2023-06-27

Family

ID=76807913

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180059453.XA Pending CN116348144A (zh) 2020-05-21 2021-05-20 用于呼吸道免疫病理学的吸入性il-1阻滞治疗

Country Status (9)

Country Link
US (1) US20230210768A1 (enExample)
EP (1) EP4153213A1 (enExample)
JP (1) JP2023526536A (enExample)
KR (1) KR20230015397A (enExample)
CN (1) CN116348144A (enExample)
AU (1) AU2021277585A1 (enExample)
CA (1) CA3178404A1 (enExample)
MX (1) MX2022014626A (enExample)
WO (1) WO2021234457A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022006636A (es) * 2019-12-02 2022-11-09 Altavant Sciences Gmbh Tratamiento de trastornos de las vías respiratorias bajas.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1565620A (zh) * 2003-06-09 2005-01-19 上海复旦张江生物医药股份有限公司 白细胞介素－1受体拮抗剂治疗非典型性肺炎的用途
US20100209357A1 (en) * 2006-08-10 2010-08-19 Levitt Roy C Localized Therapy of Lower Airways Inflammatory Disorders with Proinflammatory Cytokine Inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022006636A (es) * 2019-12-02 2022-11-09 Altavant Sciences Gmbh Tratamiento de trastornos de las vías respiratorias bajas.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1565620A (zh) * 2003-06-09 2005-01-19 上海复旦张江生物医药股份有限公司 白细胞介素－1受体拮抗剂治疗非典型性肺炎的用途
US20100209357A1 (en) * 2006-08-10 2010-08-19 Levitt Roy C Localized Therapy of Lower Airways Inflammatory Disorders with Proinflammatory Cytokine Inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GIOVANNI FILOCAMO等: "Use of anakinra in severe COVID-19: A case report", INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 11 May 2020 (2020-05-11), pages 607 - 609, XP086212762, DOI: 10.1016/j.ijid.2020.05.026 *

Also Published As

Publication number Publication date
AU2021277585A1 (en) 2022-12-15
WO2021234457A1 (en) 2021-11-25
US20230210768A1 (en) 2023-07-06
JP2023526536A (ja) 2023-06-21
MX2022014626A (es) 2023-02-22
KR20230015397A (ko) 2023-01-31
CA3178404A1 (en) 2021-11-25
EP4153213A1 (en) 2023-03-29

Similar Documents

Publication Publication Date Title
US11013691B2 (en) Heat-stable dry powder pharmaceutical compositions and methods
JP4338214B2 (ja) エリトロポエチンの肺投与
Codrons et al. Systemic delivery of parathyroid hormone (1-34) using inhalation dry powders in rats
US5284656A (en) Pulmonary administration of granulocyte colony stimulating factor
FI116195B (fi) Menetelmät ja koostumukset insuliinin antamiseksi keuhkojen kautta
JP4067047B2 (ja) 迅速な放出特性を有する吸入用粒子
JP2008163033A (ja) エアゾール化医薬の肺への送達
KR20070026604A (ko) 기관지 감염의 치료 방법
Ferrati et al. Dosing considerations for inhaled biologics
JP2006520646A (ja) 全身病の処置方法
US20220409627A1 (en) Treatment of lower airways disorders
Uchenna Agu et al. The lung as a route for systemic delivery of therapeutic proteins and peptides
CN116348144A (zh) 用于呼吸道免疫病理学的吸入性il-1阻滞治疗
Siekmeier et al. Treatment of systemic diseases by inhalation of biomolecule aerosols
US11365248B2 (en) Formulation of tocilizumab and method for treating COVID-19 by inhalation
US20220339099A1 (en) Compositions of interleukin-1 receptor antagonist
HK40095595A (zh) 用於呼吸道免疫病理学的吸入性il-1阻滞治疗
WO2024077042A2 (en) Il-1 receptor antagonist treatment for neutrophilic lung disease
KR20230118167A (ko) 다목적 적용을 위한 제형
US20210322309A1 (en) Inhalable Formulation of a Solution Containing Olodaterol

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40095595

Country of ref document: HK

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 40095595

Country of ref document: HK